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Abstract
Background: The PfEMP1 family of Plasmodium falciparum antigens play a key role in pathogenesis of severe malaria
through their insertion into the surface of parasite infected erythrocytes, and adhesion to host cells. Previous studies have
suggested that parasites expressing PfEMP1 subclasses group A and DC8, associated with severe malaria, may have a
growth advantage in immunologically naïve individuals. However, this idea has not been tested in longitudinal studies.
Methods: Here we assessed expression of the var genes encoding PfEMP1, in parasites sampled from volunteers with
varying prior exposure to malaria, following experimental infection by sporozoites (PfSPZ). Using qPCR, we tested for
associations between the expression of various var subgroups in surviving parasite populations from each volunteer and
1) the levels of participants’ antibodies to infected erythrocytes before challenge infection and 2) the apparent in vivo
parasite multiplication rate.
Results: We show that 1) expression of var genes encoding for group A and DC8-like PfEMP1 were associated with
low levels of antibodies to infected erythrocytes (αIE) before challenge, and 2) expression of a DC8-like CIDRα1.1 domain
was associated with higher apparent parasite multiplication rate in a manner that was independent of levels of prior
antibodies to infected erythrocytes.
Conclusions: This study provides insight into the role of antibodies to infected erythrocytes surface antigens in the
development of naturally acquired immunity and may help explain why specific PfEMP1 variants may be associated
with severe malaria.
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Background
When Plasmodium falciparum malaria parasites infect
erythrocytes, they insert proteins into the erythrocyte
surface that alter the properties of the infected erythro-
cyte surface. A large component of these inserted pro-
teins is P. falciparum erythrocyte membrane protein1
(PfEMP1) [1]. This family of parasite proteins play a key
role in the pathology of severe malaria by mediating the
cytoadhesion of infected erythrocytes (IE) to endothelial
cells and other uninfected erythrocytes leading to IE
sequestration in the microvasculature. This is thought to
promote parasite survival by avoiding clearance by the
spleen (reviewed in [2, 3]). Cytoadhesion is mediated by
two broad categories of adhesive domains called DBL
and CIDR domains, arranged in highly diverse combina-
tions like beads on a string [4]. Because of their
exposure on the surface of IE for long periods during
blood-stage infection, PfEMP1 are key targets of natur-
ally acquired immunity [5]. To evade host antibodies, P.
falciparum switches between around 60 members of a
diverse genomic repertoire of var genes, using an
epigenetic mechanism that ensures only one PfEMP1
antigen is expressed at any one time by each parasite [6].
The var genes within each parasite genome expressed
during childhood malaria can be broadly classified
through their upstream promotor types: every parasite
genome has a small number of var genes with ups A
and ups C promotors, with the majority having ups B
promotors [7].
The usefulness of PfEMP1 as vaccine targets is poten-
tially limited by their extreme molecular diversity [8, 9].
However, children growing up in malaria endemic areas
do develop antibodies to a broad range of PfEMP1 vari-
ants and despite their molecular diversity, expression of
restricted subclasses of relatively conserved PfEMP1 var-
iants with representative var genes in every parasite gen-
ome, have been found to be associated with severe
malaria [10–18]. The most important defined subsets of
PfEMP1 in this regard are those with an ups A promo-
tor, called “group A” and those containing CIDRα1
domains predicted to bind to endothelial protein C re-
ceptor (EPCR) [19]. Though CIDRα1 domains have been
identified within var genes with various adhesive domain
architectures, they are frequently found in the context of
commonly occurring combinations of cytoadhesive do-
mains called “domain cassettes (DC)” [7]. Two examples
of CIDRα1-containing DC reported to be associated
with severe malaria [16] are DC13 (defined as: DBLα1.7,
CIDRα1.4) and DC8 (defined as: DBLα2, CIDRα1.1,
DBLβ12, DBLγ4/6). DC13 forms a subset of group A
PfEMP1, while DC8, as strictly defined, forms a subset
of var genes with ups B promotors (group B) [7]. In
3D7, the DBLα1.7, and CIDRα1.4 domains that make up
DC13 are present within a single gene PF11_0521.
DC8 as strictly defined, is absent from 3D7. However,
PF3D7_0600200 (PFF0010w) and PF3D7_0800300
(PF08_0140) are DC8-like in every respect apart from
having CIDRα1.8 and CIDRα1.6 domains respectively
in place of CIDRα1.1. PF3D7_0400400(PFD0020c), is
DC8-like in every respect apart from having a
DBLα1.2 domain in the place of DBLα2, making it a
group A var.
The fitness advantages provided by these var gene sub-
sets associated with severe malaria are not known. It is
possible that adhesion to EPCR by CIDRα1 increases the
ability of parasites to bind to diverse endothelial cells,
hence lowering the rate of parasite clearance in the
spleen [20]. Alternatively, because group A and DC8
PfEMP1 tend to be relatively long genes they may have
more options for cytoadhesion, again allowing them an
enhanced ability to avoid passage through the spleen
and sustain infections [16, 21, 22]. Because these mole-
cules tend to be more conserved, parasites expressing
these variants tend to be recognised by children who
have a well-developed repertoire of anti-PfEMP1 anti-
bodies [23, 24]. Therefore, naturally acquired anti-
bodies against these restricted subclasses of PfEMP1
variants have been proposed to confer protection
against severe disease [25, 26].
This hypothetical trade-off between cytoadhesion and
immune escape leading to the evolution of a subclass of
PfEMP1 variants with a growth advantage in immuno-
logically naïve hosts is an attractive idea; it potentially
helps explain the development of immunity to severe
malaria in the first few years of life despite immense
overall molecular diversity in the PfEMP1 family of pro-
teins. Several pieces of evidence indirectly support the
idea. Firstly, recombinant proteins made from Group A
PfEMP1 and DC8 tend to be more commonly recog-
nized than other group B and C PfEMP1, suggesting
they are antigenically more conserved [26–28]. Secondly,
expression levels of group A-like PfEMP1 were associ-
ated with both severe malaria and absence of antibodies
at the time of disease and young host age [10]. However,
direct evidence is still needed to support 1) differential
survival of this subclass of PfEMP1 variants in the face
of different levels of pre-existing naturally acquired im-
munity and 2) an intrinsic growth advantage over other
PfEMP1 types in the absence of antibody pressure, as
opposed to a purely passive relation with prior exposure
that is driven by their relative conservation [10, 11].
Here, using a controlled human malaria infection
(CHMI) study of twenty-eight Kenyan adults infected by
intramuscular administration of aseptic, purified, cryo-
preserved NF54 (the parent line of 3D7) P. falciparum
sporozoites, (Sanaria® PfSPZ Challenge) [29], we show
that pre-existing antibodies to IE (αIE) were associated
with reduced group A and DC8-like var gene expression.
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One of three sets of primers (dc13, dc8-1 and dc8-2)
used to amplify CIDRα1 domains, dc8-1, amplified a
var signal associated with apparent in vivo parasite




An open label, randomized, CHMI pilot study using
PfSPZ Challenge (aseptic, purified, cryopreserved, infec-
tious NF54 P. falciparum sporozoites (Sanaria® PfSPZ
[30]) was undertaken in Nairobi, Kenya [29]. Briefly, in-
creasing doses of PfSPZ Challenge were administered
intramuscularly to twenty-eight volunteers with varying
degrees of prior exposure to malaria [29]. Subjects were
grouped into those with minimal prior exposure to P.
falciparum (MinExp) (n = 14) and those with definite
prior exposure to P. falciparum (DefExp) (n = 14) deter-
mined by antibody levels to recombinant merozoite sur-
face protein-2 (MSP-2) and whole schizont extract
measured prior to CHMI [29]. The rationale for using
these antigens to screen for previous exposure was based
on previous published data to support their associ-
ation with prior exposure [29, 31–33]. All subjects
were successfully infected with malaria parasites [29].
A blood sample was collected for parasite var gene
expression analysis upon blood-film positivity or at
day 21 (C + 21) post-CHMI in those undiagnosed by
this time-point. This blood sample was processed as
previously described [10, 11], with 100 μl of RBCs, de-
pleted of white blood cells, re-suspended in TRIzol and
stored at −80 °C until use. All subjects were treated with a
curative course of atovaquone/proguanil either when
blood-film positive or at C + 21.
Parasite DNA extraction and 18S ribosomal RNA gene PCR
qPCR for P. falciparum 18S ribosomal RNA (18S rRNA)
gene was performed on samples collected once or twice
daily as previously described [34]. These data were used
to calculate each subject’s PMR using simple linear re-
gression. PMR is the fold change in number of parasites
in the blood over one lifecycle (48 h). P. falciparum
schizonts usually contain approximately 20 merozoites
[35]. If these successfully invade a different red blood
cell, the PMR would be 20. In CHMI studies including
individuals with no naturally acquired immunity to
malaria, PMR has been reported to range between 10
and 15 [34, 36, 37].
Parasite RNA extraction and cDNA synthesis
Parasite RNA extraction and cDNA synthesis was
performed as previously described [10, 11].
Var transcript quantification using quantitative PCR
Primers (Table 1) previously used to quantify expression
of broad classes of var genes in qPCR [16, 38, 39] were
applied as described in [40, 41]. Two housekeeping
genes, Seryl tRNA synthetase and Fructose bisphosphate
aldolase [16, 39] were used as reference genes for rela-
tive quantification of the expressed var genes. Primers
targeting the individual var genes in 3D7 [39] were not
used as the amount of parasite RNA material available
for analysis was extremely limited given the low-density
parasitaemia present in subjects at diagnosis. The
primers used included some designed based on 3D7 gen-
ome [38] to target group A, B and C var genes (Table 1).
These included two group A-targeting primers A2 and
A3 renamed here as gpA3 and gpA4 (Table 1) that target
the exon2 region of group A genes [38]. A third broadly
specific group A primer gpA1 (originally named “Dbla1
not var3”) has been shown to amplify all DBLα domains
from group A 3D7 var genes ([16] and (Table 1).
Domain cassettes present a challenge for amplification
by qPCR because they are defined as common combina-
tions of domains whereas individual qPCR amplified
domains can occur in different molecular contexts. We
used primers designed to amplify DC8-like genes from
field isolates [16]. Here we define DC8-like genes as
those that contain individual PCR-targeted, DBL or
CIDR domain sequence features present within the ori-
ginally defined domain cassette 8 [7]. Specific data for
amplification from the NF54-derived, 3D7 genome
(Table 1) shows that dc8-1 amplifies a single group A
gene PFD0020c containing a DC8-like CIDRa1.1 do-
main, dc8-2 amplifies two DC8-like group B genes that
contain a characteristic DBLα2 domain joined to a
CIDRα1 domain, dc8-3 and dc8-4 amplify DBLβ and
DBLγ domains that are found in DC8, but in 3D7 are
found in both group A and group B genes (Table 1).
The Real-time quantitative PCR was carried out in du-
plicates in 96-well plates. The PCR reaction and cycling
conditions were carried out as described in [16] using
the Applied Biosystems 7500 Real-time PCR system with
a cycle threshold (Ct) set at 0.025 [40, 41]. Controls with
no template were included and the melt-curves analysed
for non-specific amplification. The ΔΔct relative quanti-
fication method was used to calculate the arbitrary tran-
script unit (TUs) using the formula (TUs = 2
(5-ΔΔct)).
Relative quantification is inappropriate for estimating
proportional expression. Therefore, when calculating the
proportional expression of the var subclasses, we used
TUs calculated from the formula (TUs = 2
(5-Δct)) as de-
scribed in [40, 41]. We assigned a TUs value of zero to
any reaction that did not give a detectable amplification
after 40 cycles of amplification. Only samples where we
could obtain amplification with the two housekeeping
genes were included in the analysis.
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Infected erythrocyte surface antibodies (αIE)
Plasma obtained from study participants before CHMI
was used to assess antibodies specific to IE (αIE) with
the trophozoite stages of 8 clinical isolates recently
adapted into culture [42] following isolation from chil-
dren living in Kilifi county, Kenya. In vitro, the NF54
parasite line predominantly expresses var2CSA [43, 44]
and from our experience, this line and other long-term
laboratory cultured parasite lines give poor signal when
reacted with plasma from individuals with naturally ac-
quired immunity as compared with ex vivo matured
clinical isolates. For that reason, we chose recently
culture-adapted Kenyan isolates [42] to increase the
breadth of variant surface antigens available for rec-
ognition by naturally acquired antibodies present in
the plasma of the volunteers. The 8 isolates were
mixed together in equal proportion based on parasit-
emia to make a composite of approximately 1.5%
parasitemia before reacting with the plasma from each
participant. A single plasma sample from an exposed
adult residing in Kilifi, Kenya was used as a positive
control and four from malaria-naïve Europeans plus
one-pooled European sera of AB blood group were
used as negative controls. The assay was carried out
in duplicate and in two 96-well plates, providing four
data points for each participant. Reactivity of plasma
against the IE was measured using flow cytometry
[10, 11] and presented as mean of the median fluor-
escent intensity obtained from two plates.
Anti-schizont extract and anti-MSP2 antibodies
These data were obtained using ELISA as previously
published [29].
Statistical analysis
Statistical analysis was performed using Stata version
13 and graphs were generated using GraphPad Prism
version 5.
When more than one primer was used to quantify a
certain var subclass, we calculated the median transcript
quantity obtained with the different primers to represent
the expression of the particular var subclass as described
in [40, 41]. For example, the median of DC8 (dc8_me-
dian) = the median transcript obtained with primers
dc8-1, dc8-2, dc8-3, and dc8-4, and the median of group
A (gpA_median) = the median transcript obtained with
the primers gpA1, gpA3, and gpA4. The primer to
DC13, specifically designed to target CIDRα1.4 was not
included in this global calculation because it is known to
amplify only a single var gene, PF11_0521 (Table 1).
Correlation between variables was assessed using
Spearman’s rank correlation coefficient and Bonferroni
correction was performed to adjust the p-value for mul-
tiple comparison (unless otherwise stated in the text, or
indicted with * in the tables, quoted p-values are un-
adjusted). Linear regression analysis was used to assess
whether the relationship between PMR and the tran-
script quantity of the var subclasses expressed by the in-
fecting parasites was confounded by pre-existing
Table 1 The list of primers used in this study and their predicted targets
Original primer name Name given Ref. Targets in 3D7 [16] Predicted NF54 target genes [16]






A2 gpA3 [38] Exon2 of group A var
A3 gpA4 [38] Exon2 of group A var
cidra1.4 dc13 [16] DC13 group A var (CIDRα1.4) PF11_0521
cidra1.1 dc8-1 [16] One group A, DC8-like var (CIDRα1.1) PFD0020c
dbla_cidra dc8-2 [16] Two group B, DC8-like var (DBLα2_CIDRα1) MAL6P1.316, PF08_0140
dblb12 & dblb3/5 dc8-3 [16] DC8-like var in group A and B (DBLβ12, DBLβ3) MAL6P1.316, PF08_0140, PFD0020c,
PF13_0003, PF11_0521 PFD1235w
dblg4/6 dc8-4 [16] DC8-like var in group A and B (DBLγ4, DBLγ6) PFD0020c, MAL6P1.316, PF08_0140
B1 b1 [38] Conserved upstream of group B var
C1 c1 [38] Conserved upstream of group C var
Seryl-tRNA_synthatase [39]
Fructose_biphosphase aldolase [39]
“Primer name” is the name of the primer in the original study (see reference column), “Name given” is the name given to the primer in this study. We included
the primers gpA3 and gpA4 designed based on 3D7 genome (a clone of NF54) to independently capture group A expression. Primers were previously shown to
amplify the 3D7 genes shown in the right-hand column [16]. Gene names in bold are group A var genes. New 3D7 gene names: PFD0020c = PF3D7_0400400;
PFA0015c = PF3D7_0100300; MAL6P1.314 = PF3D7_0600400; PFI1820w = PF3D7_0937600; PFD1235w = PF3D7_0425800; PFE1640w = PF3D7_0533100;
PF11_0008 = PF3D7_1100200; PF08_0141 = PF3D7_0800200; PF11_0521 = PF3D7_1150400; PF13_0003 = PF3D7_1300300;
MAL6P1.316 = PF3D7_0600200; PF08_0140 = PF3D7_0800300
Abdi et al. BMC Infectious Diseases  (2017) 17:585 Page 4 of 11
antibodies to IE (αIE). To normalize the distribution of
the data before use in regression analysis, the square
root of the explanatory variables was calculated except
for 1) group A proportional expression (gpA_prop and
gpA_prop2) that was already normally distributed and 2)
the αIE where the inverse (1/αIE) was taken.
Participant 110 from the published study [29] was ex-
cluded from analyses that includes var gene expression
data, since amplification of the reference genes was not
achieved due to the low parasitaemia.
Results
Pre-existing naturally acquired αIE differentially selects
against group A and DC8-like var gene expression
To determine whether αIE antibodies carried by each
volunteer before CHMI, imposed a selection pressure on
the PfEMP1 antigens expressed in parasites that escaped
those antibodies and established blood infection, we
tested for correlations between αIE antibodies and ex-
pression levels of var gene subclasses encoding PfEMP1
associated with low antigenic diversity. We predicted
that the parasites that establish blood-stage infection in
volunteers with low naturally acquired pre-existing αIE
antibodies would express higher levels of the conserved
var gene subclasses, group A and DC8-like compared to
those with high pre-existing αIE antibodies.
The results matched well with these predictions. The
transcript quantity obtained with one of the primers de-
signed to target the majority of group A var genes [16]
(gpA1) was negatively associated with αIE (Table 2). The
associations between gpA1 and αIE persisted after Bon-
ferroni correction for ten comparisons (corrected
p = 0.006, Table 2). The transcript quantity of two other
primers (gpA3 and gpA4) also designed to target group
A var genes and used in previously published studies
[38, 45] showed a trend towards a negative association
with αIE but with borderline significance (Table 2). The
median transcript quantity of group A var genes (gpA_-
median) as measured with the three primers gpA1,
gpA3, and gpA4 designed to globally amplify group A
var genes was negatively associated with αIE (Table 2).
However, DC13 primers, designed to amplify a subset of
group A var genes containing CIDRa1.4 domains
showed no evidence for an association with αIE
antibodies.
The transcript quantity of the four primers target-
ing sequence features found within DC8 [16] dc8-1,
dc8-2, dc8-3 and dc8-4 indicated negative trends in
relation to αIE (Table 2). dc8-2, dc8-3, and dc8-4
transcript quantity scores were significantly nega-
tively associated with αIE after Bonferroni correction
for ten comparisons (corrected p-value = 0.04, 0.05,
and 0.03 for dc8-2, dc8-3, and dc8-4 respectively,
Table 2). The median transcript quantity of the four
DC8 targeting primers (dc8_median) was also nega-
tively associated with αIE (Table 2).
Group B and group C (as measured with the primers
b1 and c1 respectively) showed no evidence for an asso-
ciation with αIE (Table 2).
In the above analyses, transcript quantities of the var
subclasses were calculated relative to the average expres-
sion of two metabolic genes. This approach does not
give information on the proportion contributed by each
var subclass to the overall var expression of the parasite
population causing the infection. To refine the analysis
and better describe the relative ability of parasites ex-
pressing different PfEMP1 types to survive within infect-
ing parasite population, we therefore estimated the
Table 2 The relationship between expression of specific var
subclasses, IE surface antibodies (αIE) and parasite multiplication
rate (PMR)
αIE PMR Parasitemia
rho p rho p rho p
Transcript quantity (individual primers)
gpA1 −0.62 0.0006* 0.44 0.02 0.08 0.7
gpA3 −0.38 0.05 0.38 0.049 0.14 0.5
gpA4 −0.37 0.05 −0.13 0.5 −0.22 0.3
dc13 0.07 0.7 −0.08 0.7 −0.03 0.9
dc8-1 −0.39 0.045 0.60 0.001* 0.18 0.4
dc8-2 −0.53 0.004* 0.43 0.03 0.13 0.5
dc8-3 −0.53 0.005* 0.13 0.5 −0.24 0.22
dc8-4 −0.56 0.003* 0.22 0.3 0.14 0.5
b1 −0.03 0.9 0.17 0.4 0.45 0.02
c1 −0.12 0.6 −0.34 0.08 −0.07 0.7
Transcript quantity (medians)
gpA_median −0.50 0.008 0.39 0.045 0.06 0.8
dc8_median −0.57 0.002 0.44 0.02 0.05 0.8
Proportional expression
gpA_prop −0.70 0.0001* 0.52 0.006* −0.04 0.9
dc8_prop −0.47 0.01 0.42 0.03 −0.08 0.7
dc13_prop 0.11 0.6 −0.11 0.6 −0.05 0.8
b1_prop 0.31 0.1 −0.06 0.8 0.38 0.05
c1_prop 0.25 0.2 −0.51 0.006* −0.15 0.4
Non-overlapping proportional expression
gpA_prop2 −0.63 0.0005* 0.50 0.007* −0.14 0.5
b1_prop2 0.33 0.1 −0.02 0.91 0.36 0.06
c1_prop2 0.28 0.2 −0.50 0.008* −0.15 0.4
Shown is the Spearman’s correlation coefficient and uncorrected p-value. The
names of the primers listed in Table 1 were used to represent the var
subclasses. *Indicate p-value that was significant after Bonferroni correction for
multiple comparisons (10, 5 and 3 comparisons for the transcript quantity,
proportional expression and non-overlapping proportional expression respectively).
PMR parasite multiplication rate, αIE antibodies to IE
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expression of each of the broad classes of the var genes
as proportion of the total measured var transcript as
previously described [40, 41] (see methods) and assessed
the relationship between the “proportional expression”
values of each of the var subclass and αIE.
Proportional expression of Group A (gpA_prop) and
DC8 (dc8_prop) showed a significant negative associ-
ation with αIE (Table 2) but only gpA_prop remained
significant after adjusting for five comparisons (ad-
justed p = 0.0005, Table 2). The associations between
group B and C proportional expression (b1_prop and
c1_prop), and αIE tended to be positive though not
significant (Table 2).
Since different defined subgroups of var genes fre-
quently carry shared sequence features, the transcript
obtained with primer sets used to quantify the different
var subclasses may overlap [40]. For examples, DC8
primers such as dc8-1 can amplify genes amplified by
both the group A primers and primer b1 while the
DC13 primer may amplify genes targeted by the group
A primers since DC13 are a subset of group A. To esti-
mate proportional expression of non-overlapping var
classes, we excluded DC8 & DC13 from the calculation
of total transcript and recalculated the proportions. With
this analysis group A proportional expression (gpA_prop2)
was negatively associated with αIE (Table 2) and remained
significant after correcting for three comparisons (cor-
rected p = 0.03).
var expression patterns exhibit differential associations with
apparent within-host parasite multiplication rate
One of the reasons proposed to explain why group A
and DC8 PfEMP1 are relatively conserved is that they
are adapted to mediate high levels of cytoadhesion
[19, 21, 22, 46] potentially giving parasites expressing
these variants a growth advantage, by lowering the
rate at which they are cleared from the circulation by
the spleen. We therefore tested the relationship be-
tween the transcript quantity of the var subclasses
and PMR using Spearman’s rank correlation coeffi-
cient. Var transcript quantities measured using indi-
vidual primer sets amplifying group A (gpA1, gpA3)
and DC8 (dc8-1, dc8-2) showed a positive trend in
relation to PMR (Table 2). However, only dc8-1
remained significantly associated with PMR after
Bonferroni correction for 10 comparisons (corrected
p = 0.01, Table 2). In contrast, no significant correl-
ation was seen between the transcript quantities of
dc13, group B (b1) and group C (c1) and PMR (Table 2).
The median transcript quantity of group A (gpA_median)
and DC8 (dc8_median) were also weakly associated with
PMR (Table 2).
As a secondary analysis, we again re-calculated these
associations using proportional expression measures.
Like the transcript quantity, group A and DC8 propor-
tional expressions (gpA_prop and dc8_prop) were
positively associated with PMR (Table 2). In contrast,
the proportional expression of group C (c1_prop) was
negatively associated with PMR (Table 2). The propor-
tional expression of DC13 and group B (dc13_prop and
b1_prop) were not associated with PMR (Table 2). The
association of both gpA_prop and c1_prop with PMR
remained significant after adjusting for five compari-
sons (adjusted p = 0.03 for both gpA_prop and
c1_prop, Table 2).
Similarly, after adjusting for possible overlap between
primers in this calculation, PMR was positively and
negatively associated with gpA_prop2 and c1_prop2 re-
spectively (Table 2). These associations remained signifi-
cant after correcting for three comparisons (adjusted
p = 0.035 & 0.04 for gpA_prop2 and c1_prop2 respect-
ively, Table 2). b1_prop2 showed no evidence for an as-
sociation with PMR (Table 2).
To exclude the possibility that the association between
expression of the different var subclasses and PMR was
an artefact of the parasitemia at the time of sampling,
we tested the relationship between the var expression
and sampling parasitemia (p/mL). Only the transcript
quantity of group B, which was not associated with
PMR, showed a significant association with parasitemia
at the time of sampling (Table 2).
Antibodies to antigens on the surface of IE (αIE) provided
an immunological correlate of low PMR
If antibodies to αIE play a direct role in the control of
parasite multiplication by decreasing parasite survival,
we would expect αIE to provide the best immunological
correlate of low PMR. We therefore made a comparison
of our measurement of αIE antibodies with previously
published data available on the volunteers [29]. In the
original study, participants were classified before CHMI
into those with definite (DefExp) and minimal (MinExp)
prior exposure to P. falciparum based on antibody levels
to schizonts extract and MSP-2 [29]. All participants
were diagnosed with malaria by blood-film apart from
one DefExp participant (110) who was blood-film nega-
tive throughout follow-up. 18S qPCR targeting riboso-
mal RNA (18S rRNA) gene confirmed this subject
was successfully infected with malaria parasites [29].
This volunteer had a reduced PMR (1.3) in compari-
son to the other twenty-seven volunteers (median
PMR = 11.1) [29].
Analysis of levels of αIE prior to CHMI showed a sig-
nificant difference between the DefExp and MinExp
groups (p = 0.0007, Fig. 1a, Mann-Whitney U test). The
differences between the two groups hold even after ex-
cluding participant 110 (p = 0.001). Participant 110
reacted to the highest proportion of IE, surpassing the
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positive control (50%, 23% and 0.65% for participant
110, the positive and negative controls respectively,
Fig. 1b-d)). αIE positively correlated with antibody
levels to both MSP-2 and schizont extract (anti-MSP-
2; rho = 0.4, p = 0.03, anti-schizont; rho = 0.67,
p = 0.0001, Fig. 1e-f ).
In these volunteers, antibodies to schizonts extract
were negatively associated with the PMR [29] and no as-
sociations were observed with antibodies against MSP-2
[29]. We therefore tested the relationship between the
αIE present before CHMI and the PMR. Consistent with
the anti-schizont antibodies, the αIE was negatively
associated with the PMR (rho = −0.45, p = 0.01, N = 28,
Fig. 1g). When we excluded participant 110 who had
very high αIE, this association remained significant
(rho = 0.4, p = 0.04, N = 27). To test how αIE compares
to anti-schizonts extract in predicting PMR, we used
two linear regression models predicting PMR using ei-
ther of them as an explanatory variable. As expected,
both antibodies predicted PMR ((coeff(95%CI), anti-
schizont = 1.0(0.16, 1.84), p = 0.02; αIE = 2.60(1.20, 4.0),
p = 0.001). However, αIE explained 33% of the variations
in PMR (adjusted R2 = 33%) while anti-schizont anti-
bodies explained only 15.6% (adjusted R2 = 15.6%), sug-
gesting αIE may be a better immunological correlate of
PMR. Results from linear regression were consistent with
those obtained using non-parametric Spearman correl-
ation analysis (associations with PMR excluding volunteer
110: MSP-2, rho = −0.13, p = 0.53; anti-schizont, −0.31,
p = 0.11; αIE, rho = −0.39, p = 0.04).
Expression of a gene containing a CIDRα1.1 is associated
with PMR independently of pre-challenge αIE antibody levels
Given that 1) both αIE and expression of specific sub-
classes of var genes were associated with PMR (Fig. 1g
and Table 2) and 2) the expression of the subclasses of
var genes were associated with the αIE (Table 2), we
sought to dissect this network of relationships further to
gain insight into possible causal pathways. Specifically,
we tested for evidence that specific var classes were
independently associated with higher PMR. We again
used linear regression models predicting PMR. All vari-
ables whose association with PMR reached an un-
adjusted p<0.05 level of significance using Spearman’s
rank correlation test (Table 2 and Fig. 1g) were used as
explanatory variables. These explanatory variables were
considered in turn in 11 separate models predicting
PMR.
To determine the level of independence of αIE and
var expression in predicting PMR, we considered each
Fig. 1 Naturally acquired pre-challenge IE surface antibodies (αIE). a Dot plot showing the αIE levels in relation to prior exposure to P. falciparum
(Mann-Whitney U test). The red bar indicates the median level. b-d shows IE surface staining of IgG from participant 110 (b), a hyperimmune Kilifi
adult (c), pooled naïve European sera (d). The upper right quadrant shows the percentage of IE recognized by the antibodies. e-f αIE association
with anti-MSP-2 (e) and anti-schizont extract (f). g Relationship between PMR and αIE, p value was calculated using Spearman’s correlation coefficient.
MinExp = minimal prior exposure, DefExp = Definite prior exposure, Neg ctrl = negative control, post ctrl = positive control. αIE = antibodies to IE,
OD = optical density, MSP-2 = merozoite surface protein 2, AB = sera from AB blood group, mdfi = median fluorescent intensity. αIE level for
participant 110 is highlighted in blue
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of the var gene expression estimates in combination
with αIE. As shown in Table 3 models 1-11, consistent
with the Spearman correlation analysis, each of the vari-
ables was significantly associated with PMR when used
as the sole explanatory variable. Overall, the results sug-
gest that the associations between expression of group A
and DC8 var subclasses and PMR is confounded by the
level of circulating αIE antibodies, as the expression of
group A and DC8 no longer remained significantly asso-
ciated with PMR after correction for prior levels of these
antibodies (group A: models 12, 13, 15, 17, 20, DC8:
models 16 and 18, Table 3).
However, 1) the expression of DC8 var amplified
with the primer dc8-1, and 2) the measure of group
C proportional expression, showed independent asso-
ciations with PMR after adjusting for αIE, positively
in the case of dc8-1 and negatively in the case of
group C (Table 3 model 14, 19 and 21). Primer dc8-1
is known to amplify a single gene PFD0020c in the
NF54-derived parasite line 3D7 [16], and expression
of this gene was not strongly associated with αIE
antibodies. This may suggest that this gene is capable
of both evading host antibodies in this group of vol-
unteers and promoting parasite survival.
Discussion
We used controlled human malaria infection of Kenyan
volunteers with varying levels of naturally acquired im-
munity to malaria to explore how parasites adapt to host
antibodies during infections, through switching between
alternative copies of PfEMP1 antigens inserted into the
surface of parasite infected erythrocytes.
The aim of this study was to examine the inter-
relationships between antibodies to parasite infected
erythrocytes (αIE) carried by volunteers before experi-
mental infection, the apparent within host multiplication
rate of parasites during the subsequent infection (PMR)
and the expression of specific sub-classes of parasite var
genes in the surviving parasite population at the time
before the infections were drug-treated. We focused on
the expression of subsets of var genes previously shown
to be associated with low host immunity and severe mal-
aria. Taken together, the results show, for the first time,
in a longitudinal study that parasite group A and DC8-
like var expression is negatively associated with levels of
αIE carried before challenge.
PfEMP1 stimulates an antibody response whose
breadth develops progressively with increasing exposure
to natural P. falciparum infections [5, 28]. To this effect,
adults that grow up in malaria-endemic regions can con-
trol parasitemia and acquire protection against clinical
malaria [47, 48]. Sera from these adults recognize many
clinical isolates [49]. This ability to control parasitemia
is thought to occur partly by preventing IE cytoadhesion
and sequestration in the organs, making them more sus-
ceptible to removal by the spleen [50–54].
Earlier serological studies emphasized the importance
of gaps in the pre-infection repertoire of protective
antibodies to specific antigenic variants in explaining
individual instances of clinical malaria [55, 56]. This sub-
sequently developed into a model of immunity in which
immune responses to a subset of dominant variants con-
ferring enhanced parasite survival (group A and DC8)
potentially explain the relatively rapid development of
immunity to severe malaria relative to non-severe mal-
aria or asymptomatic infection (Fig. 2a-c). The negative
Table 3 The relationship between αIE antibodies before CHMI,
expression of specific var subclasses after CHMI and PMR
(outcome measure). uncorrected p-values are shown
Models Explanatory
variables
Coeff(95% CI) p-value Adjusted R2
1 gpA1 1.18(0.06, 2.30) 0.04 13%
2 gpA3 1.55(0.06,3.05) 0.04 12%
3 dc8-1 1.73(0.62,2.85) 0.004 26%
4 gpA_median 0.33(0.03, 0.63) 0.03 14%
5 Dc8_median 1.32(0.07,2.58) 0.04 12%
6 gpA_prop 7.88(2.73,13.02) 0.004 26%
7 dc8_prop 7.85(−0.09,15.79) 0.05 11%
8 c1_prop −9.26(−14.85, −3.66) 0.003 29%
9 gpA_prop2 7.25(2.77,11.73) 0.003 28%
10 c1_prop2 −8.93(−14.50, −3.37) 0.003 28%
11 αIE 1.99(0.42, 3.55) 0.02 18%
12 gpA1 0.42(−1.12,1.97) 0.6 16%
αIE 1.55(−0.69,3.80) 0.17
13 gpA3 0.91(−0.69,2.52) 0.3 20%
αIE 1.54(−0.21,3.28) 0.08
14 dc8-1 1.32(0.06,2.58) 0.04 29%
αIE 1.12(−0.56,2.80) 0.2
15 gpA_median 0.18 (−0.18, 0.53) 0.3 19%
αIE 1.44 (−0.46, 3.35) 0.1
16 dc8_median 0.66(−0.81, 2.14) 0.4 18%
αIE 1.50 (−0.40, 3.41) 0.1
17 gpA_prop 6.0 (−1.08, 13.10) 0.1 25%
αIE 0.80 (−1.26, 2.85) 0.4
18 dc8_prop 4.65(−3.67, 12.96) 0.3 19%
αIE 1.59 (−0.12, 3.31) 0.07
19 c1_prop −7.31 (−13.45, −1.17) 0.02 32%
αIE 1.13 (−0.47, 2.73) 0.2
20 gpA_prop2 5.80(−0.32,11.92) 0.06 26%
αIE 0.71(−1.30,2.72) 0.5
21 c1_prop2 −7.0(−13.03, −0.95) 0.03 31%
αIE 1.18(−0.43,2.78) 0.1
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association between the naturally acquired αIE and ex-
pression of group A, DC8 and PMR is consistent with a
role for these antibodies against in vivo expansion of
parasite population (parasite burden).
If these two general ideas are combined, we arrive at a
model in which variant specific antibodies control indi-
vidual members of a subset of dominant variants. Under
this modified model of variant specific immunity to
dominant PfEMP1, we would expect to see examples of
dominant PfEMP1 that are associated with PMR, but
poorly associated with prior exposure, because of low
herd immunity in the host population (Fig. 2d). The sin-
gle group A gene PFD0020c, predicted to be amplified
by the dc8-1 primers may provide an example of such a
molecule. Unless the PFD0020c identified in the NF54-
derived line 3D7 has undergone substantial rearrange-
ment relative to the parent NF54 line used here, the re-
sults suggest that expression of a PFD0020c-like gene
was significantly associated with PMR without a signifi-
cant association with prior αIE antibodies to local iso-
lates. In support of this, PFD0020c from the 3D7 line
was notable in previous studies. 1) unlike other group A
PfEMP1, PFD0020c was poorly recognized by pooled
semi immune serum [26]; 2) in controlled infection of
naïve volunteers, this gene was dominantly expressed
[44]. It is perhaps also significant to note that the dblβ12
from this PFD0020c was recently found to bind to
gCq1R [57] raising the possibly of an immune modula-
tory effect that might conceivably reduce antibody medi-
ated clearance. Further studies are clearly needed to
quantify the expression of individual var genes in rela-
tion to domain specific antibodies against recombinant
PFD0020c domains in comparison with other PfEMP1
variants from NF54 and other local parasite isolates.
This study was limited to using primers with broad
specificity and relatively crude assays to assess anti-
body carriage before parasite challenge. However, the
results demonstrate the strong potential for the ex-
posed volunteer CHMI platform for making a detailed
dissection of the host parasite interaction during the
development of naturally acquired immunity. Recent
studies suggest that parasites may use a similar bet-
hedging strategy seen in the var genes to adapt to
changes in their host environment [58]. Several other
parasite multi-gene families (including rif and stevor
encoding exported parasite antigens and others en-
coding proteins with diverse functions, 6-cys, clag,
etramp, acs, fikk and phist a,b and c) are expressed
in a clonally variant manner. Future studies using a
combination of protein arrays to make fine grained
measures of pre-challenge antibodies and parasite
RNAseq to assess how infecting parasite populations
collectively respond to antibody pressure may now
provide direct insight into how parasites establish and
maintain infections.
Conclusions
In summary, the results show that 1) naturally acquired
αIE antibodies carried before controlled infection with
NF54 strain PfSPZ appear to protect preferentially
against Group A, and DC8-like var gene expression 2)
expression of a var gene predicted to encode a DC8-like
PfEMP1 similar to 3D7 PFD0020c, was associated with
higher PMR after CHMI. We propose that, in non-
immune individuals, absence or low αIE antibodies
contributes to a reduction in parasite clearance
resulting in increased apparent parasite multiplica-
tion rate (PMR). Within such a model, interventions
targeting specific subsets of PfEMP1 may reduce
parasite growth in vivo which may in turn reduce
malaria associated mortality and morbidity.
Fig. 2 Proposed model to explain the inter-relationships between
antibodies, var expression and apparent parasite multiplication rate
(PMR). a In the absence of αIE antibodies, parasites expressing a sub-
set of “dominant” PfEMP1 with high intrinsic cytoadhesive capacity
dominate the infection (black) because of their ability to limit splenic
parasite clearance rate. b As a result, these variants will be the first
to be recognized by the developing host antibody response. c
The surviving parasites express PfEMP1 variants that can evade anti-
bodies, but because they have a lower intrinsic cytoadhesive capacity,
these parasites have a higher splenic clearance rate, resulting in a
lower observed apparent PMR. The thick grey horizontal line repre-
sents the endothelial cells that make up the inner wall of microvessels.
d under a model of variant specific immunity, dominant variants (or-
ange shapes) may arise that are poorly recognised by antibodies carried
by the host population (grey rectangles) allowing them to establish in-
fections (arrows). Their expression levels would be correlated with
growth rate but poorly correlated with bulk measures of
pre-infection antibodies
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